

Jessica Flynn
230 W 82nd Street Apt 2A,
New York, NY 10024
flynnj@mskcc.org | 631-766-3040

Education

Columbia University Mailman School of Public Health

M.S. Biostatistics, Theory and Methods Track

2018 - 2020

New York, NY

Cornell University

B.S Biometry & Statistics | Minors: Demographics; Nutrition & Health

2013 - 2017

Ithaca, NY

Research

Memorial Sloan Kettering Cancer Center, Department of Epidemiology & Biostatistics

January 2019- Present

Data Analyst II

New York, NY

- Conduct statistical analysis on clinical oncology data using methods such as survival analysis, logistic regression, and nonparametric statistical tests in R
- Collaborate with clinicians and oncology researchers to prepare abstracts and manuscripts for publication
- Engage in weekly seminars and clinical trial protocol reviews

Data Analyst

June 2017- January 2019

Cognitive Neuroscience Lab

September 2014 – May 2017

Research Assistant

Ithaca, NY

- Helped graduate students run experiments involving language acquisition and memory
- Learned how computational modeling applies to cognitive neuroscience
- Attended weekly lab meetings held by Professor Morten Christiansen

Social and Decision Analytics Lab, Biocomplexity Institute of Virginia Tech

National Science Foundation Research Experience for Undergraduates (NSF REU)

May 2016 – July 2016

Summer Fellow

Arlington, VA

- Assisted with big data cleaning, profiling, and analytics with a focus on State Longitudinal Data Systems
- Collaborated on team project to create criteria for open data portals and presented to Arlington County executives in the Chief Information Office
- Co-authored article for August 2016 AMSTAT News, a magazine for the American Statistical Association
- Created and presented project materials to local, state, and federal sponsors at the end of the fellowship

Teaching

Cornell University Biological Statistics Department

August 2016 – May 2017

Teaching Assistant / Peer Advisor

Ithaca, NY

- Ran a weekly lab course to teach R Statistical Software and introductory statistics to 30 students
- Held a weekly office hour to support students and answer questions regarding course material and assignments
- Assisted in grading homework assignments and proctoring exams
- Provided guidance to incoming biometry and statistics students regarding course selection
- Served as a mentor to help promote academic success within the major

Publications

1. Santomasso BD, Park JH, Salloom D, Riviere I, **Flynn J**, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ. (2018). Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL). *Cancer Discovery*, <https://doi.org/10.1158/2159-8290.CD-17-1319>
2. Tufts LS, Jarnagin ED, **Flynn J**, Gonen M, Guiliem JG, Paty PB, Nash GM, Smith JJ, Wei IH, Pappou E, Allen PJ, Kingham PT, Balachandran VP, Drebin JA, Garcia-Aguilar J, Jarnagin WR, Weiser MR (2018). A perioperative multidisciplinary care bundle reduces surgical site infections in patients undergoing synchronous colorectal and liver resection. *HPB*, <https://doi.org/10.1016/j.hpb.2018.07.001>.
3. Kurilova I, Beets-Tan R, **Flynn J**, Gonen M, Ulaner G, Petre EN, Boas FE, Ziv E, Yarmohammadi H, Klompenhouwer EG, Cercek

- A, Kemeny N, Sofocleous CT (2018). Factors Affecting Oncologic Outcomes of 90Y Radioembolization of Heavy Pre-Treated Patients With Colon Cancer Liver Metastases. *Clinical Colorectal Cancer*, <https://doi.org/10.1016/j.clcc.2018.08.004>.
4. Turashvili G, Gomez-Hidalgo NR, **Flynn J**, Gonen M, Leitao MM, Soslow RA, Murali R (2018). Risk-based stratification of carcinomas concurrently involving the endometrium and ovary. *Gynecologic Oncology*, <https://doi.org/10.1016/j.ygyno.2018.10.033>
5. Wang C, Rimmer A, Gelblum DY, **Flynn J**, Jackson A, Yorke E, Wu AJ (2019). Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors. *JAMA Oncology*, doi:10.1001/jamaoncol.2019.0205
6. Braunstein LZ, Thor M, **Flynn J**, Cost Z, Wilgucki M, Rosenbaum S, Zhang Z, Gillespie E, McCormick B, Khan A, Ho A, Cahlon O, Deasy JO, Powell SN (2019). Daily Fractionation of External Beam Accelerated Partial Breast Irradiation to 40 Gy Is Well Tolerated and Locally Effective. *International Journal of Radiation Oncology Biology Physics*, <https://doi.org/10.1016/j.ijrobp.2019.02.050>
7. Qureshi T, Veeraraghavan H, Sung JS, Kaplan JB, **Flynn J**, Tonorezos ES, Wolden SL, Morris EA, Oeffinger KC, Pike MS, Moskowitz CS (2019). Automated Breast Density Measurements From Chest Computed Tomography Scans. *Journal of Medical Systems*, <https://doi.org/10.1007/s10916-019-1363-9>
8. Fitzgerald K, **Flynn J**, Zhang Z, Cost Z, Mueller B, Gillespie EF, McCormick B, Khan A, Cahlon O, Powell SN, Braunstein LZ (2019). Patterns of Recurrence Among Higher Risk Patients Receiving Daily External Beam Accelerated Partial Breast Irradiation to 40 Gy in Ten Fractions. *Advances in Radiation Oncology*, <https://doi.org/10.1016/j.adro.2019.07.017>
9. Schwarzkopf E, Sachdev R, **Flynn J**, Boddapati V, Padilla RE, Prince DE (2019). Occurrence, risk factors, and outcomes of bone cement implantation syndrome after hemi and total hip arthroplasty in cancer patients. *Journal of Surgical Oncology*, <https://doi.org/10.1002/jso.25675>
10. Silagy AW, **Flynn J**, Mano R, Blum KA, Marcon J, DiNatale RG, Sanchez A, Carlo MI, Motzer RJ, Coleman JA, Russo P, Ostrovnaya I, Chen YB, Hakimi A (2019). Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. *Urologic Oncology*, <https://doi.org/10.1016/j.urolonc.2019.07.011>
11. Miller ME, Muhsen S, Zabor EC, **Flynn J**, Olcese C, Giri D, Van Zee KJ, Pilewskie M (2019). Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma In Situ. *Annals of Surgical Oncology*, <https://doi.org/10.1245/s10434-019-07796-9>
12. Bartlett EK, **Flynn JR**, Panageas KS, Ferraro RA, Sta Cruz JM, Postow MA, Coit DG, Ariyan CE (2019). High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy. *Cancer*, <https://doi.org/10.1002/cncr.32506>
13. Mano R, **Flynn J**, Blum KA, Silagy AW, DiNatale RG, Marcon J, Wang A, Sanchez A, Coleman JA, Russo R, Ostrovnaya I, Hakimi AA (2019). The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. *Urologic Oncology*, <https://doi.org/10.1016/j.urolonc.2019.09.006>
14. Bhatia A, Birger M, Veeraraghavan H, Um H, Tixier R, McKenney AS, Cugliari M, Caviasco A, Bialczak A, Malani R, **Flynn J**, Zhang Z, Yang TJ, Santomaso BD, Shoushtari AN, Young RJ (2019). MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. *Neuro-Oncology*, <https://doi.org/10.1093/neuonc/noz141>
15. Christian N, Zabor EC, Cassidy M, **Flynn J**, Morrow M, Gemignani ML (2019). Contralateral Prophylactic Mastectomy Use After Neoadjuvant Chemotherapy. *Annals of Surgical Oncology*, <https://doi.org/10.1245/s10434-019-08038-8>
16. Ho AY, Barker CA, Arnold BB, Powell SN, Hu ZI, Gucalp A, Lebron-Zapata L, Wen HY, Kallman C, D'Agnolo A, Zhang Z, **Flynn J**, Dunn SA, McArthur HL (2019). A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. *Cancer*, <https://doi.org/10.1002/cncr.32599>
17. Shah RJ, Korenstein D, **Flynn JR**, Koo DJ (2019). Resource Utilization in Hospitalized Patients With Cancer From Hospice Decision to Discharge and Provider-Type Differences. *American Journal of Hospice and Palliative Medicine*, <https://doi.org/10.1177/1049909119889289>
18. Umemura Y, Wang D, Peck KK, **Flynn J**, Zhang Z, Fatovic R, Anderson ES, Beal K, Shoushtari AN, Kaley T, Young RJ (2019). DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. *Journal of Neuro-Oncology*, <https://doi.org/10.1007/s11060-019-03379-6>
19. Sun H, Vachha B, Laino ME, Janabi M, **Flynn JR**, Zhang Z, Holodny AI, Peck KK (2020). Decreased Hand Motor Resting-State Functional Connectivity in Patients with Glioma: Analysis of Factors including Neurovascular Uncoupling. *Radiology*, <https://doi.org/10.1148/radiol.2019190089>
20. Yu AF, **Flynn JR**, Moskowitz CS, Scott JM, Oeffinger KC, Dang CT, Liu JE, Jones LW, Steingart RM (2020). Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer. *JAMA Cardiology*, doi: 10.1001/jamacardio.2019.5586
21. Walsh SM, Zabor EC, **Flynn J**, Stempel M, Morrow M, Gemignani ML (2020). Breast cancer in young black women. *British Journal of Surgery*, <https://doi.org/10.1002/bjs.11401>
22. Mota JM, Barnett E, Nauseef JT, Nguyen B, Stopsack KH, Wibmer A, **Flynn JR**, Heller G, Danila DC, Rathkopf D, Slovin S,

Kantoff PW, Scher HI, Morris MJ, Schultz N, Solit DB, Abida W (2020). Platinum-Based Chemotherapy in Metastatic Prostate Cancer with DNA Repair Gene Alterations. *JCO Precision Oncology*, 10.1200/PO.19.00346 *JCO Precision Oncology* no. 4 (2020) 355-366

23. Ahmed ZU, **Flynn J**, Riedel ER, Huryn JM, Rosen EB (2020). Definitive maxillary obturator prosthesis: Timelines for fabrication and follow-up. *Special Care in Dentistry*, <https://doi.org/10.1111/scd.12471>
24. Root JC, Campbell C, Rocha-Cadman X, Kasven-Gonzalez N, Maloy M, **Flynn J**, Devlin SM, Jakubowski AA (2020). Pre-transplant cognitive dysfunction in advanced-age hematologic cancers: predictors and associated outcomes. *Biology of Blood and Bone Marrow Transplant*, <https://doi.org/10.1016/j.bbmt.2020.05.010>
25. Wudhikarn K, Pennisi M, Garcia-Recio M, **Flynn JR**, Afuye A, Silverberg ML, Maloy MA, Devlin SM, Batlevi C, Shah GL, Scordo M, Palomba M, Dahi PB, Sauter CS, Santomaso BD, Mead E, Perales MA (2020). DLBCL Patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. *Blood Advances*, <https://doi.org/10.1182/bloodadvances.2020001972>
26. Wang C, Rimner A, Gelblum DY, Dick-Godfrey R, McKnight D, Torres D, **Flynn J**, Zhang Z, Sidiqi B, Jackson A, Yorke E, Wu AJ (2020). Analysis of pneumonitis and esophageal injury after stereotactic body radiation therapy for ultra-central lung tumors. *Lung Cancer*, <https://doi.org/10.1016/j.lungcan.2020.07.009>
27. Wudhikarn K, Palomba ML, Pennisi M, Garcia-Recio M, **Flynn JR**, Devlin SM, Afuye A, Silverberg ML, Maloy MA, Shah GL, Scordo M, Dahi PB, Sauter CS, Batlevi CL, Santomaso BD, Mead E, Seo SK, Perales MA (2020). Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. *Blood Cancer Journal*, <https://doi.org/10.1038/s41408-020-00346-7>
28. Mondaca SP, Liu D, **Flynn JR**, Badson S, Hamaway S, Gounder MM, Khalil DN, Drilon AE, Li BT, Jhaveri KL, Schram AM, Kargus Ke, Kasler MK, Blauvelt NM, Segal NH, Capanu M, Callahan MK, Hyman DM, Gambarian-Gelwan M, Harding JJ (2020). Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. *Cancer*, <https://doi.org/10.1002/cncr.33153>
29. Hakimi AA, Attalla K, DiNatale RG, Ostrovnaya I, **Flynn J**, Blum KA, Ged Y, Hoen D, Kendall SM, Reznik E, Bowman A, Hwee J, Fong CJ, Kuo F, Voss MH, Chan TA, Motzer RJ (2020). A pan-cancer analysis of PBAF complex mutations and their associations with immunotherapy response. *Nature Communications*, <https://doi.org/10.1038/s41467-020-17965-0>
30. McBride S, Sherman E, Tsai CJ, Baxi S, Aghalar J, Eng J, Zhi WI, McFarland D, Michel LS, Young R, Lefkowitz R, Spielsinger D, Zhang Z, **Flynn J**, Dunn L, Ho A, Riaz N, Pfister D, Lee N (2020). Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. *Journal of Clinical Oncology*, 10.1200/JCO.20.00290
31. Dickinson SM, McIntyre CA, Schilsky JB, Harrington KA, Gerst SR, **Flynn JR**, Gonen M, Capanu M, Wong W, Lawrence S, Allen PJ, O'Reilly EM, Jarnagin WR, D'Angelica MI, Balachandran VP, Drebin JA, Kingham PT, Simpson AL, Do RK (2020). Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. *Abdominal Radiology*, <https://doi.org/10.1007/s00261-020-02726-w>
32. Maitland ML, Wilkerson J, Karovic S, Zhao B, **Flynn J**, Zhou M, Hilden P, Ahmed FS, Dercle L, Moskowitz CS, Tang Y, Connors DE, Adam SJ, Kelloff GJ, Gonen M, Fojo AT, Schwartz LH, Oxnard GR (2020). Enhanced detection of treatment effects on metastatic colorectal cancer with volumetric CT measurements for tumor burden growth rate evaluation. *Clinical Cancer Research*, 10.1158/1078-0432.CCR-20-1493
33. Sermer D, Batlevi C, Palomba M, Shah G, Lin RJ, Perales MA, Scordo M, Dahi P, Pennisi M, Afuye A, Silverberg ML, Ho C, **Flynn J**, Devlin S, Caron P, Hamilton A, Hamlin P, Horwitz S, Joffe E, Kumar A, Matasar M, Noy A, Owens C, Moskowitz A, Straus D, von Keudell G, Rodriguez-Rivera I, Falchi L, Zelenetz A, Yahalom J, Younes A, Sauter C (2020). Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. *Blood Advances*, <https://doi.org/10.1182/bloodadvances.2020002118>
34. Bitencourt A, Rossi Saccarelli C, Morris EA, **Flynn J**, Zhang Z, Khan A, Gillespie e, Cahlon O, Mueller B, Cuaron JJ, McCormick B, Powell SN, Plitas G, Razavi P, Pinker K, Riedl CC, Sutton EJ, Braunstein LZ (2020). Regional Lymph Node Involvement Among Patients With De Novo Metastatic Breast Cancer. *JAMA Network Open*,
35. Byun DJ, Braunstein R, **Flynn J**, Zheng J, Lefkowitz RA, Kanbour S, Girotra M (2020). Immune Checkpoint Inhibitor-Associated Diabetes: A Single Institution Experience. *Diabetes Care*,
36. Geyer MB, Ritchie EK, Rao AV, Vemuri S, **Flynn J**, Hsu M, Devlin SM, Roshal M, Gao Q, Shukla M, Salcedo JM, Maslak P, Tallman MS, Douer D, Park JH (2020). Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. *Haematologica*,

Abstracts

1. Tufts LS, Jarnagin ED, **Flynn J**, Gonen M, Guillem JG, Paty PB, Nash GM, Smith JJ, Wei IH, Dematteo RP, D'Angelica MI, Allen PJ, Kingham TP, Balachandran VP, Garcia-Aguilar J, Jarnagin WR, Weiser MR. (2018). Multidisciplinary, perioperative care bundle

decreases surgical site infection in patients undergoing synchronous colorectal/liver resection. *Americas Hepato-Pancreato-Biliary Association*, <https://doi.org/10.1016/j.hpb.2018.02.037>

2. Cho C, **Flynn J**, Devlin SM, Maloy M, Giralt SA, Koehne G, Maslak O, O'Reilly RJ, Smith K, Tonon J, Avecilla ST, Perales M. (2018). Universal Engraftment after Allogeneic HCT Using Cryopreserved CD34+ Cell-Selected Grafts. *American Society for Blood and Marrow Transplantation*, <https://doi.org/10.1016/j.bbmt.2017.12.046>
3. Root JC, Rocha-Cadman X, Kasven-Gonzalez N, Campbell C, Maloy M, **Flynn J**, Devlin SM, Jakubowski AA. (2018). Pre-Transplant Cognitive Dysfunction in Hematologic Cancers, Predictors and Associated Outcomes. *American Society for Blood and Marrow Transplantation*, <https://doi.org/10.1016/j.bbmt.2017.12.354>
4. Kim J, Schattner M, Ludwig E, Mendelsohn R, Markowitz A, **Flynn J**, Riedel E, Gerdes H, Shah P. (2018). Efficacy and Long-Term Outcomes of Endoscopic Self-Expanding Metal Stents in Malignant Gastric Outlet Obstruction. *Digestive Disease Week*, <https://doi.org/10.1016/j.gie.2018.04.1668>
5. Santomaso B, Haggiagi A, Malani R, Maher C, Holder JN, Shames U, Wilcox J, **Flynn J**, Briggs S, Panageas K, Callahan M. (2018). Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade. *American Society of Clinical Oncology (ASCO) Meeting*, http://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.3581
6. Hilden P, Gonen M, Connors DE, Tang Y, Zhao B, Yang H, Karovic S, **Flynn J**, Adam S, Fojo A, Kelloff G, Maitland ML, Oxnard GR, Schwartz LH, Moskowitz CS. (2018). Early response metrics for predicting trial outcomes: A report from volumetric CT for precision analysis of clinical trials (Vol-PACT). *American Society of Clinical Oncology (ASCO) Meeting*, http://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.3581
7. McBride SM, Sherman EJ, Tsai CJ, Baxi SS, Aghalar J, Eng J, Zhi WI, McFarland DC, Michel LS, Spielsinger D, Zhang Z, **Flynn J**, Dunn L, Ho AL, Riaz N, Pfister DG, Lee NY. (2018). A Phase II randomized trial of nivolumab with stereotactic body radiotherapy (SBRT) versus nivolumab alone in metastatic (M1) head and neck squamous cell carcinoma (HNSCC). *American Society of Clinical Oncology (ASCO) Meeting*, http://ascopubs.org/doi/10.1200/JCO.2018.36.15_suppl.6009
8. Fitzgerald KJ, **Flynn J**, Zhang Z, Gillespie EF, Khan AH, Cahlon O, McCormick B, Powell SN, Braunstein LZ. (2018). Accelerated Partial Breast Irradiation in Guideline-Defined Suitable and Cautionary Patients. *American Society for Radiation Oncology Conference*, <https://doi.org/10.1016/j.ijrobp.2018.07.1612>
9. Miller ME, Muhsen S, Zabor EC, **Flynn J**, Olcese C, Giri D, Van Zee KJ, Pilewskie M. (2018). Risk of contralateral breast cancer (CBC) in women with ductal carcinoma in situ (DCIS) with and without synchronous lobular carcinoma in situ (LCIS). *San Antonio Breast Cancer Symposium*, DOI: 10.1158/1538-7445.SABCS18-P5-18-01
10. Lee JO, **Flynn J**, Maloy M, Jakubowski AA, Papadopoulos EB, Cho C, Ponce D, Sauter CS, Perales M, Devlin SM, Giralt S, Castro-Malaspina HR, Tamari R (2018). CD34+ Selected Hematopoietic Stem Cell Transplants Conditioned with a Myeloablative Regimen Is Well Tolerated and Results in Good Outcomes in Patients with Myelofibrosis. *American Society of Hematology Conference*, <https://doi.org/10.1182/blood-2018-99-113166>
11. Pianko MJ, Tiutan T, **Flynn J**, Devlin SM, Jaffer-Sathick I, Rossi AC, Salvatore SP, Landau HJ, Lendvai N, Smith EL, Korde N, Mailankody S, Lesokhin AM, Hultcrantz M, Chung DJ, Giralt S, Landgren O, Hassoun H (2018). Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience. *American Society of Hematology Conference*, <https://doi.org/10.1182/blood-2018-99-112110>
12. Modlin LA, **Flynn J**, Zhang Z, Mueller B, Khan AJ, Gillespie EF, Cahlon O, McCormick B, Ronson ME, Powell SN, Braunstein LZ (2019). Breast Radiotherapy Among ATM-Mutation Carriers. *American Society of Clinical Oncology (ASCO) Meeting*, https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.1504?af=R
13. Perica K, **Flynn J**, Curran KJ, Wang X, Halton E, Diamonte C, Pineda J, Bernal Y, Gonen M, Riviere I, Sadelain M, Brentjens RJ, Park JH (2019). Impact of Bridging Chemotherapy on Clinical Outcome of CD19 CAR T Therapy in Adult ALL. *American Society of Clinical Oncology (ASCO) Meeting*, https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.2520
14. Hakii AA, Ged Y, **Flynn J**, Hoen DR, Di Natale RG, Blum KA, Makarov V, Kuo F, Carlo MI, Lee CH, Ostrovnya I, Chan TA, Motzer RJ (2019). The Impact of PBRM1 on Overall Survival in greater than 2,100 Patients Treated with Immune Checkpoint Blockade (ICB). *American Society of Clinical Oncology (ASCO) Meeting*, https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.666
15. Lin RJ, Elko TA, Devlin SM, **Flynn J**, Jakubowski AA, Shahrokni A, Dahi P, Perales M, Sanchez-Escamilla M, Tamari R, Shaffer BC, Sauter CS, Papadopoulos EB, Castro-Malaspina H, Gyurkocza B, Barker JN, Maloy MA, Korc-Grodzicki B, Giralt S (2019). Impact of geriatric vulnerability on outcomes of older patients in allogeneic hematopoietic cell transplantation. *American Society of Clinical Oncology (ASCO) Meeting*, https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.7017
16. Khan AJ, Bilena C, Wilgucki M, **Flynn J**, Modlin LA, Tadros AB, Razavi P, Braunstein LZ, Gillespie EF, Cahlon O, McCormick B, Zhang Z, Morrow M, Powell SN (2019). Breast Cancer in Patients Age <=35 Years: Overall Survival, Disease-Free Survival, Secondary Malignancies, and Contralateral Breast Cancer Rates across 10 Years of Follow-up. *American Society for Radiation Oncology Conference*, <https://doi.org/10.1016/j.ijrobp.2019.06.673>
17. Max D, **Flynn J**, Zhang Z, Mueller BA, Gillespie EF, Khan AJ, Cahlon O, Powell SN, McCormick B, Braunstein LZ (2019). Breast-Conserving Therapy for DCIS: Local Recurrence Following Boost Radiotherapy. *American Society for Radiation Oncology Conference*, <https://doi.org/10.1016/j.ijrobp.2019.06.648>

18. Haseltine J, Happersett L, **Flynn J**, Kollmeier M, McBride S, Gorovets D, Zhang Z, Mulhall J, Varghese M, Zelefsky MJ (2019). Predictors of Sexual Function Outcome after Stereotactic Body Radiotherapy for Localized Prostate. *American Society for Radiation Oncology Conference*, <https://doi.org/10.1016/j.jrobp.2019.06.1907>
19. Pennisi M, Sanchez-Escamilla M, **Flynn J**, Maloy MA, Silverberg ML, Batlevi Y, Shouval R, Batlevi C, Brentjens RJ, Devlin SM, Dahi PB, Diamonte C, Giralt SA, Halton E, Jain T, Mean E, Palomba M, Santomasso B, Sauter CS, Scordo M, Shan GL, Park JH, Perales M (2019). Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells. *American Society of Hematology Conference*, <https://doi.org/10.1182/blood-2019-126208>
20. Park JH, **Flynn J**, Gonen M, Bernal Y, Diamonte C, Halton E, Xiuyan X, Riviere I, Sadelain M, Brentjens RJ (2019). Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL. *American Society of Hematology Conference*, <https://doi.org/10.1182/blood-2019-129343>
21. Piedra KM, Hassoun H, Buie LW, Devlin SM, **Flynn J**, Hultcrantz M, Lesokhin AM, Lu SX, Mailankody S, Shah UA, Smith EL, Landgren O, Korde N, Peterson TJ (2019). VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis. *American Society of Hematology Conference*, <https://doi.org/10.1182/blood-2019-124403>
22. Pennisi M, Jain T, Mead E, Santomasso B, Silverberg ML, Batlevi Y, Shouval R, Maloy MA, Devlin SM, Batlevi C, Brentjens RJ, Dahi PB, Diamonte C, **Flynn J**, Giralt SA, Halton E, Palomba M, Sanchez-Escamilla M, Sauter CS, Scordo M, Shah GL, Park JH, Perales M (2019). Comparing Gratings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management. *American Society of Hematology Conference*, <https://doi.org/10.1182/blood-2019-126022>
23. Wudhikarn K, Pennisi M, Recio MG, **Flynn J**, Maloy MA, Devlin SM, Batlevi CW, Shah GL, Scordo M, Palomba LM, Dahi PB, Sauter CS, Perales M (2020). Burden and Impact of Toxicities on Outcomes for Aggressive B Cell Non-Hodgkin Lymphoma Patients after CD-19 Directed Chimeric Antigen Receptor T Cell: Real-World Experience. *American Society for Transplant and Cellular Therapy Conference*, <https://doi.org/10.1016/j.bbmt.2019.12.428>
24. Lin A, Dahi PB, **Flynn J**, Uruburo C, Mcgeary I, Schofield R, Bhatt V, DeRespiris L, Figgins B, Griffin M, Laur C, Proli AJ, Carlow D, Cho C, Lahoud OB, Perales M, Sauter CS, Scordo M, Shah GL (2020). Effect of Melphalan Exposure in Patients with Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT). *American Society for Transplant and Cellular Therapy Conference*, <https://doi.org/10.1016/j.bbmt.2019.12.472>
25. Attalla K, Duzgol C, McLaughlin L, **Flynn J**, Ostrovnaya I, DiNatale RG, Silagy AW, Coleman J, Lee C, Carlo M, Voss MH, Russo P, Bilsky A, Hakimi AA, Moss N (2020). The spinal distributions of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination. *American Society of Clinical Oncology Conference*, 10.1200/JCO.2020.38.6_suppl.742 *Journal of Clinical Oncology* 38, no. 6_suppl (February 20, 2020) 742-742.
26. Shamseddine A, **Flynn J**, Zhang Z, Morrow M, Mueller B, Gillespie E, Khan A, McCormick B, Cahlon O, Powell S, Barrio A, Braunstein LZ (2020). In-breast pathologic complete response (pCR) following neoadjuvant chemotherapy predicts nodal pCR in early stage breast cancer. *American Association for Cancer Research*, 10.1158/1538-7445.SABCS19-P2-16-06
27. Goldfarb SB, Saban S, Arkema A, Patil S, **Flynn J**, Goldfrank DJ, Norton L, Carter J (2020). Objective and subjective vulvovaginal symptoms in breast cancer patients. *American Society of Clinical Oncology Conference*, [10.1200/JCO.2020.38.15_suppl.e24056](https://doi.org/10.1200/JCO.2020.38.15_suppl.e24056)
28. Maguire K, **Flynn J**, Panageas K, Fessele K (2020). You Again? Frequency of Oncologic Emergency Visits to a Comprehensive Cancer Center Urgent Care Center: A Descriptive Cohort Study. *Oncology Nursing Society Conference*,

Presentations

- “Partly Conditional Modeling.” ASCO Conference (FNIH Team), Chicago, IL, June 2, 2019
- “Navigating Relationships in Multicenter Collaborations.” Women in Statistics and Data Science Conference, Bellevue, WA, October 5, 2019